Literature DB >> 10976661

Double jeopardy: schizophrenia and substance use.

C D Swofford1, G Scheller-Gilkey, A H Miller, B Woolwine, R Mance.   

Abstract

OBJECTIVE: Although the clinical reality of substance dependence and/or abuse among schizophrenia patients is widely acknowledged, the interaction of these diagnoses is not well understood. Perhaps the largest study documenting the comorbidity of substance abuse is the Epidemiologic Catchment Area (ECA) study, which found the rate to be 47% in schizophrenia patients (1). The present study examined substance use and compared the broad categories of substance users versus nonusers vis-à-vis schizophrenic symptomatology, hospitalizations, compliance, and demographic variables. We further examined the two subcategories of alcohol versus other substances of abuse (hereafter called "drugs") to determine differences.
METHODS: Data were collected by the same person retrospectively from the charts of schizophrenia outpatients in a public inner city mental health center. Patients must have had at least 10 outpatient visits within a 2-year period for data to be used.
RESULTS: Data were compiled from 262 charts. Of the schizophrenia patients, 55% had a history of past or current substance use. Consistent with previous reports, substance-using schizophrenia patients were more likely to be younger and male than nonusers. Substance users had significantly more hospitalizations and more outpatient visits with positive symptoms. There was also a higher rate of missed appointments in the substance-using patients, and there was a correlation between missed appointments and hospitalizations. As for the differences in the two subcategories of alcohol versus drugs, drug users had notably more negative symptoms, except in those cases for which the alcohol user required treatment for alcoholism. Current drug use also correlated with higher tardive dyskinesia scores, higher incidence of cognitive deficiency, less education, and higher average neuroleptic dose than with nonuse or alcohol use.
CONCLUSION: These results extend the previous findings to a large inner city group of subjects and to a population that is at high risk for relapse. Our findings further emphasize the impact of substance use on outcome in schizophrenia and the need for more research on the nature and treatment of the patient with a dual diagnosis.

Entities:  

Mesh:

Year:  2000        PMID: 10976661     DOI: 10.1081/ada-100100248

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  13 in total

Review 1.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

2.  The associations between substance use disorders, schizophrenia-spectrum disorders, and Axis IV psychosocial problems.

Authors:  Michael T Compton; Paul S Weiss; Joyce C West; Nadine J Kaslow
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-10-25       Impact factor: 4.328

3.  Substance use and cognition in early psychosis.

Authors:  Alissa Pencer; Jean Addington
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

4.  Latent class analysis of discordance between results of drug use assessments in the CATIE data.

Authors:  Kiersten L Johnson; Sarah L Desmarais; Marvin S Swartz; Richard A Van Dorn
Journal:  Schizophr Res       Date:  2014-12-01       Impact factor: 4.939

5.  The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

Authors:  Maju Mathew Koola; Heidi J Wehring; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2012

Review 6.  Assessing the value of antipsychotics for treating schizophrenia: the importance of evaluating and interpreting the clinical significance of individual service costs.

Authors:  Sandra L Tunis; Haya Ascher-Svanum; Michael Stensland; Bruce J Kinon
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

7.  Factors associated with substance use problem among Maryland Medicaid enrollees affected by serious mental illness.

Authors:  Krista Schladweiler; Pierre K Alexandre; Donald M Steinwachs
Journal:  Addict Behav       Date:  2009-05-20       Impact factor: 3.913

8.  Changes over time and disparities in schizophrenia treatment quality.

Authors:  Alisa B Busch; Anthony F Lehman; Howard Goldman; Richard G Frank
Journal:  Med Care       Date:  2009-02       Impact factor: 2.983

Review 9.  [Dual diagnosis of psychosis and addiction. From principles to practice].

Authors:  E Gouzoulis-Mayfrank
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

10.  Substance use disorders in schizophrenia--clinical implications of comorbidity.

Authors:  Nora D Volkow
Journal:  Schizophr Bull       Date:  2009-03-26       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.